Skip to main
OTLK

OTLK Stock Forecast & Price Target

OTLK Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 0%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Outlook Therapeutics Inc. has experienced a positive trajectory in its commercial operations following the launch of its ophthalmic formulation ONS-5010/LYTENAVA, obtaining $1.4 million in revenue within the first month of its launch in Germany and the UK, and showing an increase in both the number of accounts ordering the product and the breadth of prescribing physicians in early FY2026. The company's solid performance in the NORSE EIGHT trial, demonstrating noninferiority to ranibizumab, combined with a strategic collaboration for commercial support, strengthens the potential for rapid revenue growth in the near term. Additionally, the company's current valuation appears attractive, as indicated by a positive NPV analysis, suggesting significant upside potential from its present share price.

Bears say

Outlook Therapeutics Inc. faces considerable challenges impacting its financial outlook due to rapid declines in the theranibizumab market and uncertain commercial viability for its lead product, ONS-5010, which may struggle against intensified competition from novel drugs and biosimilars. The company's R&D expenses saw a significant reduction to $27.2 million in FY2025, a decline from $41.8 million the previous year, suggesting potential budget constraints amid ongoing risks related to product development and market dynamics. Additionally, the failure of the NORSE EIGHT clinical study to meet its non-inferiority endpoint, along with regulatory hurdles, may further complicate the pathway to profitability and necessitate additional financing, raising concerns about potential shareholder dilution.

OTLK has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 0% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Outlook Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Outlook Therapeutics Inc (OTLK) Forecast

Analysts have given OTLK a Buy based on their latest research and market trends.

According to 4 analysts, OTLK has a Buy consensus rating as of Jan 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.88, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.88, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Outlook Therapeutics Inc (OTLK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.